VV ECMO Cannulation: Should I Stay or Should I Go?

Mazzeffi, Michael; Galvagno, Samuel M.; Menaker, Jay

doi:10.1053/j.jvca.2018.11.044

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VV-ECMO is considered an assisting modality for reversible lung diseases with respiratory failure when traditional methods are ineffective. [43]…”

Section: Discussionmentioning

confidence: 99%

“…[42] VV-ECMO is considered an assisting modality for reversible lung diseases with respiratory failure when traditional methods are ineffective. [43] Much remains mysterious about 2019-CoV, and solid clinical evidence is lacking regarding the role of ECMO in rescuing critical illnesses. Despite the application of ECMO in China and recommendations on ECMO by the WHO and Chinese experts in COVID-19, several fundamental questions remain unanswered, including the benefit, timing, indications, management, and risks of ECMO, as well as global sharing of evidence from trials.…”

Section: Ecmomentioning

confidence: 99%

See 1 more Smart Citation

Does the variant positivity and negativity affect the clinical course in COVID-19?: A cohort study

Yıldırım¹,

Kiliçkan²,

Aksoy³

et al. 2023

Medicine

View full text Add to dashboard Cite

The primary aim of the current study is to analyze the clinical, laboratory, and demographic data comparing the patients with Coronavirus Disease 2019 (COVID-19) admitted to our intensive care unit before and after the UK variant was first diagnosed in December 2020. The secondary objective was to describe a treatment approach for COVID-19. Between Mar 12, 2020, and Jun 22, 2021, 159 patients with COVID-19 were allocated into 2 groups: the variant negative group (77 patients before December 2020) and the variant positive group (82 patients after December 2020). The statistical analyses included early and late complications, demographic data, symptoms, comorbidities, intubation and mortality rates, and treatment options. Regarding early complications, unilateral pneumonia was more common in the variant (−) group (P = .019), whereas bilateral pneumonia was more common in the variant (+) group (P < .001). Regarding late complications, only cytomegalovirus pneumonia was observed more frequently in the variant (−) group (P = .023), whereas secondary gram (+) infection, pulmonary fibrosis (P = .048), acute respiratory distress syndrome (ARDS) (P = .017), and septic shock (P = .051) were more common in the variant (+) group. The therapeutic approach showed significant differences in the second group such as plasma exchange and extracorporeal membrane oxygenation which is more commonly used in the variant (+) group. Although mortality and intubation rates did not differ between the groups, severe challenging early and late complications were observed mainly in the variant (+) group, necessitating invasive treatment options. We hope that our data from the pandemic will shed light on this field. Regarding the COVID-19 pandemic, it is clear that there is much to be done to deal with future pandemics. Abbreviations: ARDS = acute respiratory distress syndrome, ARF = acute respiratory failure, CMV = cytomegalovirus, CoV = Coronavirus, COVID-19 = Coronavirus disease 2019, CPAP = continous positive airway pressure, ECMO = extracorporeal membrane oxygenator, HFNC = high flow nasal cannula, ICU = intensive care unit, MAS = macrophage activating syndrome, MOF = multi-organ failure, nCPAP = nasal continous positive airway pressure, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, VV-ECMO = veno venous extracorporeal oxygenator.

show abstract

“…VV-ECMO is considered an assisting modality for reversible lung diseases with respiratory failure when traditional methods are ineffective. [43]…”

Section: Discussionmentioning

confidence: 99%

Section: Ecmomentioning

confidence: 99%

Does the variant positivity and negativity affect the clinical course in COVID-19?: A cohort study

Yıldırım¹,

Kiliçkan²,

Aksoy³

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…VV-ECMO provides extracorporeal oxygen supply via the oxygenator, leading to improved oxygenated blood supply to the heart and organs with a minimal pulmonary workload. VV-ECMO is largely used in intensive care unit (ICU) patients with reversible lung dysfunction and respiratory failure [11] and can also be indicated in some cases as a bridge to lung transplant [12].…”

Section: Vv-ecmomentioning

confidence: 99%

Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs

Abidi¹,

Nekidy

Atallah

et al. 2023

JCM

View full text Add to dashboard Cite

There has been a substantial increase in the use of extracorporeal membrane oxygenation (ECMO) support in critically ill adults. Understanding the complex changes that could affect drugs’ pharmacokinetics (PK) and pharmacodynamics (PD) is of suitable need. Therefore, critically ill patients on ECMO represent a challenging clinical situation to manage pharmacotherapy. Thus, clinicians’ ability to predict PK and PD alterations within this complex clinical context is fundamental to ensure further optimal and, sometimes, individualized therapeutic plans that balance clinical outcomes with the minimum drug adverse events. Although ECMO remains an irreplaceable extracorporeal technology, and despite the resurgence in its use for respiratory and cardiac failures, especially in the era of the COVID-19 pandemic, scarce data exist on both its effect on the most commonly used drugs and their relative management to achieve the best therapeutic outcomes. The goal of this review is to provide key information about some evidence-based PK alterations of the drugs used in an ECMO setting and their monitoring.

show abstract

“…The oxygenated blood directly enters the pulmonary artery to participate in the circulation, reducing pulmonary circulation resistance and right ventricular afterload ( Figure 1A ). Because of its unique cardiopulmonary-protective effect, VV-ECMO is considered as an assisting modality for reversible lung diseases with respiratory failure when traditional methods are not effective [ 45 ]. Thanks to advances in technology, its indications have been greatly expanded, and VV-ECMO can now be the preferred treatment option in patients with acute respiratory failure (ARF) who meet the indications [ 46 ].…”

Section: Basic Knowledge Of Ecmomentioning

confidence: 99%

Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

Liang

Ding

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

VV ECMO Cannulation: Should I Stay or Should I Go?

Cited by 3 publications

References 6 publications

Does the variant positivity and negativity affect the clinical course in COVID-19?: A cohort study

Does the variant positivity and negativity affect the clinical course in COVID-19?: A cohort study

Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs

Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

Contact Info

Product

Resources

About